SNGX:OTCQB

Soligenix Inc.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company maintains two active business segments: BioTherapeutics and Vaccines/BioDefense.
The BioTherapeutics business segment is developing a first-in-class photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, and a novel innate defense regulator (IDR) technology, dusquetide (SGX942), for the treatment of oral mucositis in head-and-neck cancer.
SNGX:OTCQB

Expert Comments:

Maxim Group biotech analyst Jason Kolbert notes "steady progress" is being made by Soligenix Inc., a small-cap biotech with programs addressing bioterrorism threats and a devastating side effect of cancer treatment, in his Q1/16 update on the company.
read more >
Jason Kolbert, Maxim Group (6/7/16)
"Preliminary results from Soligenix Inc.'s SGX942 Phase 2 study in oral mucositis will be presented by Dr. Oreola Donini, Chief Scientific Officer and Dr. Richard Straube, Chief Medical Officer, at the Multinational Association for Supportive Care in Cancer conference in Adelaide, Australia, on June 25, 2016. . .the company is planning a pivotal Phase 2b/3 study. . .positive preliminary results from the SGX942 Phase 2 study set the stage for a Phase 2b/3 study. We are excited for the potential of this molecule to really have an impact in an area that represents a truly unmet medical need."

Grant Zeng, Zacks Small-Cap Research (5/16/16)
"Soligenix Inc. built a diversified pipeline targeting multiple indications. We are optimistic about its lead candidates SGX301 for CTLC and SGX942 for the treatment of oral mucositis. Soligenix's oral BDP is in various development stages. . .Soligenix is developing vaccines using its ThermoVax technology for biodefense."

Jason Kolbert, Maxim Group (5/12/16)
Soligenix Inc. reported Q1/16 results with total revenues of $2.6M. . .the company released positive data from the Phase 2 oral mucositis study with SGX942 this past quarter. SGX942's novel mechanism of action as an Innate Defense Regulator showed the potential to address all stages of oral mucositis disease progression. . .the positive preliminary results of the SGX942 Phase 2 study sets the stage for Soligenix to pursue partnerships for the Phase 2/3 study. We are excited for the potential of this molecule to really have an impact in an area that represents a truly unmet medical need."

Grant Zeng, Zacks Small-Cap Research (5/6/16)
"We think [NIAID's] exercise of [the RiVax] option not only boosts Soligenix Inc.'s balance sheet, more importantly, it validates the company's vaccine technology and its ongoing commitment to advance development of viable thermostabilization vaccines. . .RiVax has been granted orphan drug designation by the FDA for the prevention of ricin intoxication. Assuming development efforts are successful for RiVax, potential government procurement contract(s) could reach $200M."

Jason Kolbert, Maxim Group (5/5/16)
"Soligenix Inc. will receive an additional $4.3M as part of an exercised option under the original contract with NIAID for the development of the company's thermostabilization technology for a RiVax vaccine. . .the continued nondilutive government funding for biodefense research is positive. . .the positive preliminary results of the SGX942 Phase 2 study sets the stage for Soligenix to pursue partnerships for the Phase 2/3 study. We are excited for the potential of this molecule to really have an impact in an area that represents a truly unmet medical need."

Management Q&A: View From the Top
Christopher Schaber
With a robust pipeline of drugs in late-stage clinical trials and milestones on the horizon, it's no wonder Soligenix Inc.'s CEO, Dr. Christopher Schaber, holds an optimistic view of the company's future.
read more >
Grant Zeng, Zacks Small-Cap Research (4/20/16)
"Soligenix Inc. plans to meet with the FDA as soon as possible to discuss the next step of development of SGX942 for the treatment of oral mucositis. . .simultaneous with the FDA meeting, the company will be aggressively pursuing opportunities for partnership to support subsequent clinical trials with SGX942. With the compelling data from the Phase 2 trial, it's our belief that it should be relatively easy to find a partner with favorable terms." -Zacks Small-Cap Research

More Expert Comments

Experts Following This Company

Jason Kolbert, Senior Analyst – Maxim Group
Jason McCarthy, Analyst – Maxim Group
Ross Silver, Co-Founder and Principal Analyst – Vista Partners
Grant Zeng, Senior Biotech Analyst – Zacks Investment Research, Zacks Small-Cap Research

The information provided above is from analysts, newsletters, the company and other contributors.

Soligenix Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
 
Two Phase 3 pivotal trials in CTCL and pediatric Crohn's disease and a Phase 2 trial in oral mucositis in head and neck cancer
 
Positive Phase 2 clinical data with SGX942 in oral mucositis in head and neck cancer patients
 
Up to $57M in government contract funding
catalyst Calendar